- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02382653
Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain
The Analgesic Efficacy of Oral Piroxicam Versus Buccal Fentanyl in Cancer Breakthrough Pain in Patients With Bone Metastases
100 patients with Breakthrough pain will be allocated to receive either oral prioxicam (OP) (n=50) or sublingual fentanyl (SLF) (n=50) . Patients will be divided randomly into two equal groups: oral prioxicam (OP) Group and sublingual fentanyl citrate (SLF) Group, comprising of 50 patients each.
Pain intensity level on a 0-10 visual analog scale (VAS), patients will be instructed about the use of a 10-cm visual analog scale (VAS) (0 = no pain to 10 = worst possible pain). frequency of Breakthrough pain throughout the day, onset of relief (0-5, 6-10, 11-15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment.
Study Overview
Detailed Description
In this prospective, longitudinal, controlled-study, 100 patients with Breakthrough pain will be allocated to receive either oral prioxicam (OP) (n=50) or sublingual fentanyl (SLF) (n=50) . Patients will be divided randomly into two equal groups: oral prioxicam (OP) Group and sublingual fentanyl citrate (SLF) Group, comprising of 30 patients each.
Eligible participants were all adults aged 18 or over suffering from Background pain cancer pain whose cancer pain was treated with strong opioids and who had breakthrough pain which met the criteria described by Portenoy.(5) (stable analgesia in the previous 48 h, controlled background pain in the previous 24 h, transient exacerbation of pain in the previous 24 h). The term strong opioid refers to medicines classified as being on step three of the World Health Organization (WHO) analgesic ladder. In Egypt the strong opioids available include fentanyl, morphine and hydromorphone.
Exclusion criteria were less than18 years old, non-controlled basal pain, hospitalized patients, or cognitive disturbances, patients with contraindication to NSAIDS such as gastric ulcer, impaired renal function, cerebrovascular accident, Coronary artery bypass graft , Uncontrolled hypertension, patients with coagulation anomalies such as hepatic disease or patients a previous history of allergy to NSAID.
Randomization will be performed by random numbers using sealed envelopes without sex stratification. Sealed envelopes indicate the group of assignment. An independent anesthesiologist, who did not participate in the study or data collection, will read the number contained in the envelope and made group assignments. Patients will be blindly randomized to the two groups; the process of inclusion into the study will go on until the requested number of patients will be reached.
Pain intensity level on a 0-10 visual analog scale (VAS), patients will be instructed about the use of a 10-cm visual analog scale (VAS) (0 = no pain to 10 = worst possible pain). frequency of Breakthrough pain throughout the day, onset of relief (0-5, 6-10, 11-15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment.
The primary outcome is the degree of breakthrough pain score using VAS in the two groups. The secondary outcomes measures are analgesic requirement, patients satisfaction, and identification of undesirable effects that may be associated with the use of both drugs in patients with breakthrough pain in both groups. All adverse events related to surgery and the regional anesthetic technique will be recorded.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Eligible participants were all:
- adults aged 18 or over
- suffering from Background pain cancer pain
- whose cancer pain was treated with strong opioids and
- who had breakthrough pain which met the criteria described by Portenoy.
Exclusion Criteria:
Exclusion criteria were:
- less than18 years old,
- non-controlled basal pain,
- hospitalized patients, or cognitive disturbances,
patients with contraindication to NSAIDS such as:
- gastric ulcer,
- impaired renal function,
- cerebrovascular accident,
- coronary artery bypass graft,
- uncontrolled hypertension,
- patients with coagulation anomalies such as hepatic disease or
- patients a previous history of allergy to NSAID.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: oral perixicam
50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
|
Oral adminstration of buccal perixicam
Other Names:
|
No Intervention: oral fentanyl
50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
analgesic scale (assessmet of VAS immeditally after analgesic adminstration)
Time Frame: two hours
|
assessmet of VAS immeditally after analgesic adminstration
|
two hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ayman A Yousef, Assistant professor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Pain
- Neurologic Manifestations
- Neoplastic Processes
- Neoplasm Metastasis
- Breakthrough Pain
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Piroxicam
Other Study ID Numbers
- 2970/12/14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasm Metastases
-
Rutgers, The State University of New JerseyRecruitingPalliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone MetasMetastases, Neoplasm | Neoplasm MetastasesUnited States
-
Azienda Ospedaliera di PadovaIstituto Oncologico Veneto IRCCSRecruitingColorectal Adenocarcinoma | Colorectal Liver Metastases | Unresectable Malignant NeoplasmItaly
-
University of CalgaryNot yet recruitingBone Metastases | Spine Metastases | Bone LesionCanada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBone Metastases | Cancer Survivor | Metastatic Malignant Neoplasm in the BoneUnited States
-
Betta Pharmaceuticals Co., Ltd.Recruiting
-
Shanghai Changzheng HospitalNot yet recruiting
-
Chinese University of Hong KongNot yet recruitingBone Metastases
-
University Hospital, GhentFlemish institute of biotechnology (VIB)RecruitingPeritoneal MetastasesBelgium
-
National Taiwan University HospitalRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Accuray IncorporatedRecruiting
Clinical Trials on oral perixicam
-
Université de MontréalSt. Justine's HospitalTerminatedObstructive Sleep ApneaCanada
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
Pulmagen TherapeuticsCompleted
-
Mansoura UniversityCompletedSmall Bowel ObstructionEgypt
-
Turning Point Therapeutics, Inc.RecruitingLymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS TumorsUnited States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
-
German Institute of Human NutritionLudwig-Maximilians - University of MunichCompletedDiabetes | Pre-diabetesGermany
-
Applied Molecular TransportActive, not recruitingUlcerative ColitisUnited States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
-
Brigham and Women's HospitalCompletedSleep Apnea, ObstructiveUnited States
-
WockhardtCompleted
-
Mayo ClinicNational Center for Advancing Translational Sciences (NCATS)Completed